ASTech leadership in The Analytical Scientist Power List 2015

ASTech leadership in The Analytical Scientist Power List 2015

October 22, 2015

ASTech Training Centre Director Emily Hilder and Chief Investigator Paul Haddad have been celebrated again amongst the top 100 most influential people in the world of analytical science, as published in The Analytical Scientist Power List for 2015.

Professor Emily Hilder was also featured in The Analytical Scientist's Power Lists in 2013 and 2014. Emeritus Professor Haddad has been placed at #13 for 2015, and was also featured in the list for 2013.

Their acknowledgment by this publication highlights their ongoing significant contributions to the field.

Read more at The Analytical Scientist:

Read more about ASTech.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More